Current Oncology Reports

, Volume 8, Issue 1, pp 7–13 | Cite as

Advances in breast imaging: Magnetic resonance imaging



Magnetic resonance imaging (MRI) of the breast is rapidly becoming incorporated into clinical practice. Indications for breast MRI include staging of known breast cancer, monitoring response to chemotherapy, assessing recurrence, problem solving, and high-risk screening. Magnetic resonance spectroscopy is a promising technique that may decrease the number of benign biopsies generated by breast MRI in the clinical setting.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kaiser WA, Zeitler E: MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989, 170:681–686.PubMedGoogle Scholar
  2. 2.
    Heywang SH, Wolf A, Pruss E, et al.: MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989, 171:95–103.PubMedGoogle Scholar
  3. 3.
    Orel SG, Schnall MD, Powell CM, et al.: Staging of suspected breast cancer: effect of MR imaging and MRguided biopsy. Radiology 1995, 196:115–122.PubMedGoogle Scholar
  4. 4.
    Fischer U, Kopka L, Grabbe E: Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999, 213:881–888.PubMedGoogle Scholar
  5. 5.
    Liberman L, Morris EA, Dershaw DD, et al.: MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003, 180:901–910.PubMedGoogle Scholar
  6. 6.
    Berg WA: Imaging the local extent of disease. Semin Breast Dis 2001, 4:153–173.Google Scholar
  7. 7.
    Bedrosian I, Mick R, Orel SG, et al.: Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003, 98:468–473.PubMedCrossRefGoogle Scholar
  8. 8.
    Mumtaz H, Hall-Craggs MA, Davidson T, et al.: Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997, 169:417–424.PubMedGoogle Scholar
  9. 9.
    Schelfout K, Van Goethem M, Kersschot E, et al.: Contrastenhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004, 30:501–507.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee SG, Orel SG, Woo IJ, et al.: MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003, 226:773–778.PubMedCrossRefGoogle Scholar
  11. 11.
    Frei KA, Kinkel K, Bonel HM, et al.: MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol 2000, 175:1577–1584.PubMedGoogle Scholar
  12. 12.
    Orel SG, Reynolds C, Schnall MD, et al.: Breast carcinoma: MR imaging before re-excisional biopsy. Radiology 1997, 205:429–436.PubMedGoogle Scholar
  13. 13.
    Faverly DR, Hendriks JH, Holland R: Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer 2001, 91:647–659.PubMedCrossRefGoogle Scholar
  14. 14.
    Knopp. MR mammography with pharmocokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. MRI Clin North Am 1997, 2:633–658.Google Scholar
  15. 15.
    Esserman L, Kaplan E, Partridge S, et al.: MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001, 8:549–559.PubMedCrossRefGoogle Scholar
  16. 16.
    Wasser K, Klein SK, Fink C, et al.: Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003, 13:80–87.PubMedGoogle Scholar
  17. 17.
    Delille JP, Slanetz PJ, Yeh ED, et al.: Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 2003, 228:63–69.PubMedCrossRefGoogle Scholar
  18. 18.
    Gilles R, Guinebretiere JM, Shapeero LG, et al.: Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993, 188:473–478.PubMedGoogle Scholar
  19. 19.
    Dao TH, Rahmouni A, Campana F, et al.: Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993, 187:751–755.PubMedGoogle Scholar
  20. 20.
    Olson JA Jr, Morris EA, Van Zee KJ, et al.: Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000, 7:411–415.PubMedCrossRefGoogle Scholar
  21. 21.
    Schorn C, Fischer U, Luftner-Nagel S, et al.: MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999, 9:470–473.PubMedCrossRefGoogle Scholar
  22. 22.
    Campana F, Fourquet A, Ashby MA, et al.: Presentation of axillary lymphadenopathy without detectable breast primary (T0 N1b breast cancer): experience at Institut Curie. Radiother Oncol 1989, 15:321–325.PubMedCrossRefGoogle Scholar
  23. 23.
    Morris EA, Schwartz LH, Dershaw DD, et al.: MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 1997, 205:437–440.PubMedGoogle Scholar
  24. 24.
    Orel SG, Weinstein SP, Schnall MD, et al.: Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999, 212:543–549.PubMedGoogle Scholar
  25. 25.
    Kuhl CK, Schmutzler RK, Leutner CC, et al.: Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000, 215:267–279.PubMedGoogle Scholar
  26. 26.
    Warner E, Plewes DB, Shumak RS, et al.: Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001, 19:3524–3531.PubMedGoogle Scholar
  27. 27.
    Morris EA, Liberman L, Ballon DJ, et al.: MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003, 181:619–626.PubMedGoogle Scholar
  28. 28.
    Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317–1325. This study has clearly documented the risks and benefits of breast MRI screening in women at the highest levels of hereditary risk. Again, results strongly suggest that women with BRCA mutations should be offered such screening.PubMedCrossRefGoogle Scholar
  29. 29.
    Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427–437. This study provides data on almost twice as many patients and twice as many mutation carriers as were included in all previously published evaluations of MRI in high-risk patients combined. Results from this study strongly suggest that women with BRCA mutations should be offered MRI screening.PubMedCrossRefGoogle Scholar
  30. 30.
    Morris EA, Harms S: ACR practice guideline for the performance of magnetic resonance imaging (MRI) of the breast. ACR 2004, 269-274.Google Scholar
  31. 31.
    ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. Reston, VA: ACR; 2003.Google Scholar
  32. 32.
    Holland R, Veling SH, Mravunac M, Hendriks JH: Histologic multifocality of Tis, T1-2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer 1985, 56:979–990.PubMedCrossRefGoogle Scholar
  33. 33.
    Quan ML, Sclafani L, Heerdt AS, et al.: Magnetic resonance imaging detects unsuspected disease in patients with invasive lobular cancer. Ann Surg Oncol 2003, 10:1048–1053.PubMedCrossRefGoogle Scholar
  34. 34.
    Weinstein SP, Orel SG, Heller R, et al.: MR imaging of the breast in patients with invasive lobular carcinoma. AJR Am J Roentgenol 2001, 176:399–406.PubMedGoogle Scholar
  35. 35.
    Hwang ES, Kinkel K, Esserman LJ, et al.: Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003, 10:381–388.PubMedCrossRefGoogle Scholar
  36. 36.
    Viehweg P, Lampe D, Buchmann J, Heywang-Kobrunner SH: In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging. Magma 2000, 11:129–137.PubMedGoogle Scholar
  37. 37.
    Morris EA, Schwartz LH, Drotman MB, et al.: Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000, 214:67–72.PubMedGoogle Scholar
  38. 38.
    Liberman L: Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size. AJR Am J Roentgenol 2005, in press.Google Scholar
  39. 39.
    Partridge SC, Gibbs JE, Lu Y, et al.: Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002, 179:1193–1199.PubMedGoogle Scholar
  40. 40.
    Buist DS, Porter PL, Lehman C, et al.: Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 2004, 96:1432–1440.PubMedCrossRefGoogle Scholar
  41. 41.
    Liberman L: Breast cancer screening with MRI: what are the data for patients at high risk? N Engl J Med 2004, 351:497–500.PubMedCrossRefGoogle Scholar
  42. 42.
    Boetes C, Stoutjesdijk M: MR imaging in screening women at increased risk for breast cancer. Magn Reson Imaging Clin N Am 2001, 9:357–372, vii.PubMedGoogle Scholar
  43. 43.
    Morris EA: Review of breast MRI: indications and limitations. Semin Roentgenol 2001, 36:226–237.PubMedCrossRefGoogle Scholar
  44. 44.
    Orel SG, Schnall MD: MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001, 220:13–30.PubMedGoogle Scholar
  45. 45.
    Negendank W: Studies of human tumors by MRS: a review. NMR Biomed 1992, 5:303–324.PubMedGoogle Scholar
  46. 46.
    Mackinnon WB, Barry PA, Malycha PL, et al.: Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997, 204:661–666.PubMedGoogle Scholar
  47. 47.
    Aboagye EO, Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80–84.PubMedGoogle Scholar
  48. 48.
    Yeung DK, Yang WT, Tse GM: Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 2002, 225:190–197.PubMedCrossRefGoogle Scholar
  49. 49.
    Yeung DK, Cheung HS, Tse GM: Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. Radiology 2001, 220:40–46.PubMedGoogle Scholar
  50. 50.
    Kvistad KA, Bakken IJ, Gribbestad IS, et al.: Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999, 10:159–164.PubMedCrossRefGoogle Scholar
  51. 51.
    Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE: The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001, 68:45–54.PubMedCrossRefGoogle Scholar
  52. 52.
    Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE: Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998, 209:269–275.PubMedGoogle Scholar
  53. 53.
    Gribbestad IS, Singstad TE, Nilsen G, et al.: In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998, 8:1191–1197.PubMedCrossRefGoogle Scholar
  54. 54.
    Tse GM, Cheung HS, Pang LM, et al.: Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 2003, 181:1267–1272.PubMedGoogle Scholar
  55. 55.
    Bolan PJ, Meisamy S, Baker EH, et al.: In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003, 50:1134–1143.PubMedCrossRefGoogle Scholar
  56. 56.
    Huang W, Fisher PR, Dulaimy K, et al.: Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004, 232:585–591.PubMedCrossRefGoogle Scholar
  57. 57.
    Jacobs MA, Barker PB, Bottomley PA, et al.: Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004, 19:68–75.PubMedCrossRefGoogle Scholar
  58. 58.
    Jagannathan NR, Kumar M, Seenu V, et al.: Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001, 84:1016–1022.PubMedCrossRefGoogle Scholar
  59. 59.
    Meisamy S, Bolan PJ, Baker EH, et al.: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy—a pilot study at 4 T. Radiology 2004, 233:424–431.PubMedCrossRefGoogle Scholar
  60. 60.
    Bartella L: Proton MR spectroscopy (MRS) using choline signal as malignancy marker improves specificity compared to conventional MRI in diagnosis of breast cancer: a preliminary study. Radiology 2004, 233:505.CrossRefGoogle Scholar
  61. 61.
    Demartini WB, Lehman CD, Peacock S, Russell MT: Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers after neoadjuvant chemotherapy. Acad Radiol 2005, 12:806–814.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  1. 1.Department of Radiology, Memorial Sloan-Kettering Cancer CenterWeill Medical College Of Cornell UniversityNew YorkUSA

Personalised recommendations